article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapy products, unveiling a major shift in approach to the issue.

article thumbnail

Merkin Prize in Biomedical Technology awarded to F. William Studier for development of widely used protein- and RNA-production platform

Broad Institute

I've always been interested in solving problems,” Studier told Brookhaven National Laboratory in a 2011 profile. When he launched his own lab at Brookhaven National Laboratory in 1964, Studier focused on sequencing the genes of the T7 bacteriophage and understanding the function of each of its corresponding proteins during infection of E.

RNA 84
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. With all these diverse methods we characterise protein-ligand interactions in many ways. 2011) D67, 386-394) using PDB ID 4GV1 which was published as part of Addie et al.

article thumbnail

The Codon Guide to Synthetic Biology

Codon

Nature (2011). Link Gene Expression & Regulation →Genetic regulatory mechanisms in the synthesis of proteins , by Jacob F. & Link The PURE system for the cell-free synthesis of membrane proteins , by Kuruma Y. & Link The Elaboration of the Central Dogma. Scitable, by Nature Education. & Xie X.S.

DNA 98
article thumbnail

Key considerations before commencing cell line development

Drug Target Review

5 And for the latter, the development of a technique to temporally track gene expression in CHO cells, which therefore has the potential to lead to the identification of targets to improve recombinant protein production. 2011), 108: 2141-2150 Schmieder V, Fieder J, et al. 2016), 32: 1301-1307 Matasci M, Baldo L, et al.

article thumbnail

The Codon Guide to Synthetic Biology

Codon

Nature (2011). Link Gene Expression & Regulation →Genetic regulatory mechanisms in the synthesis of proteins , by Jacob F. & Link The PURE system for the cell-free synthesis of membrane proteins , by Kuruma Y. & Link The Elaboration of the Central Dogma. Scitable, by Nature Education. & Xie X.S.

DNA 52
article thumbnail

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

Results demonstrated a substantial decrease in the time to diagnosis from >6 years of age (2011-2015) to <2 years of age (2019-2020). of all patients. About STK-001. STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in a Phase 1/2a clinical trial.